These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anaemia by bone marrow stem cell expression of the tumour necrosis factor receptor. Kasahara S, Hara T, Itoh H, Ando K, Tsurumi H, Sawada M, Yamada T, Ohnishi H, Moriwaki H. Br J Haematol; 2002 Jul; 118(1):181-8. PubMed ID: 12100146 [Abstract] [Full Text] [Related]
3. Expression of the proliferating cell nuclear antigen in bone marrow cells from patients with myelodysplastic syndromes and aplastic anemia. Kitagawa M, Kamiyama R, Kasuga T. Hum Pathol; 1993 Apr; 24(4):359-63. PubMed ID: 8098317 [Abstract] [Full Text] [Related]
4. Ki-S1 and proliferating cell nuclear antigen expression of bone marrow macrophages. Immunohistochemical and morphometric study including reactive (inflammatory) myelitis, secondary aplastic anemia, AIDS, myelodysplastic syndromes and primary (idiopathic) osteomyelofibrosis. Titius BR, Thiele J, Schaefer H, Kreipe H, Fischer R. Acta Haematol; 1994 Apr; 91(3):144-9. PubMed ID: 7522384 [Abstract] [Full Text] [Related]
6. CD34 and p53 immunohistochemical stains differentiate hypocellular myelodysplastic syndrome (hMDS) from aplastic anemia and a CD34 immunohistochemical stain provides useful survival information for hMDS. Cha CH, Park CJ, Chi HS, Seo EJ, Jang S, Cho YU, Lee KH, Lee JH, Lee JH, Im HJ, Seo JJ. Ann Lab Med; 2014 Nov; 34(6):426-32. PubMed ID: 25368817 [Abstract] [Full Text] [Related]
9. [Changes of CD34(+) and CD71(+)CD45(-) cell levels in bone marrow of MDS and AA patients]. Yan ZY, Tian X, Li Y, Yang MR, Zhang S, Wang XM, Zhang HX, Cheng NY. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):382-6. PubMed ID: 24763009 [Abstract] [Full Text] [Related]
10. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Matsui WH, Brodsky RA, Smith BD, Borowitz MJ, Jones RJ. Leukemia; 2006 Mar; 20(3):458-62. PubMed ID: 16437138 [Abstract] [Full Text] [Related]
13. Immunophenotype of myeloid granulocytes: a pilot study for distinguishing myelodysplastic syndrome and aplastic anemia by flow cytometry. Huang M, Li J, Zhao G, Sui X, Zhao X, Xu H. Int J Lab Hematol; 2010 Jun; 32(3):275-81. PubMed ID: 19968721 [Abstract] [Full Text] [Related]
18. AIDS-related bone marrow lesions--myelodysplastic features or predominant inflammatory-reactive changes (HIV-myelopathy)? A comparative morphometric study by immunohistochemistry with special emphasis on apoptosis and PCNA-labeling. Thiele J, Zirbes TK, Bertsch HP, Titius BR, Lorenzen J, Fischer R. Anal Cell Pathol; 1996 Aug; 11(3):141-57. PubMed ID: 8888951 [Abstract] [Full Text] [Related]
19. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Barrett J, Saunthararajah Y, Molldrem J. Semin Hematol; 2000 Jan; 37(1):15-29. PubMed ID: 10676908 [Abstract] [Full Text] [Related]
20. Quantification of marrow CD34+ cells: An important tool for distinguishing between hypoplastic myelodysplastic syndromes and aplastic anemia. Orazi A. Leukemia; 2006 Nov; 20(11):2041; author reply 2041-2. PubMed ID: 16990766 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]